Identification of novel mutations in Spanish patients with muscle carnitine palmitoyltransferase II deficiency

M A Martín1, J C Rubio, P del Hoyo

  • 1Centro de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain.

Human Mutation
|June 22, 2000
PubMed

Insights

Carnitine palmitoyltransferase II (CPT II) deficiency, a common lipid metabolism disorder, causes muscle issues and myoglobinuria. Genetic analysis revealed diverse mutations in Spanish patients, highlighting the need for ethnic considerations in diagnosis.

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic Disorders

Background:

  • Carnitine palmitoyltransferase II (CPT II) deficiency is a prevalent inherited metabolic disorder.
  • It primarily affects skeletal muscle, leading to hereditary myoglobinuria.

Purpose of the Study:

  • To investigate the clinical and molecular characteristics of CPT II deficiency in Spanish patients.
  • To identify novel mutations and understand the genetic heterogeneity of the disease.

Main Methods:

  • Studied five Spanish patients with CPT II deficiency from four families.
  • Performed clinical evaluation, including assessment of myoglobinuria and creatine kinase levels.
  • Conducted molecular analysis by amplifying and sequencing the CPT2 gene to identify mutations.

Main Results:

  • Four patients presented with typical muscle CPT II deficiency symptoms like myoglobinuria and elevated creatine kinase.
  • One patient exhibited exercise-related myalgia and cramps without myoglobinuria.
  • Identified known mutations (S113L, P50H, 178 insT/del 25 bp) and three novel mutations (Y120C, 36-38 insGC, I502T).

Conclusions:

  • CPT II deficiency exhibits significant molecular heterogeneity.
  • Ethnic origin should be considered in mutation analysis for CPT II deficiency.

Related Concept Videos